Larimar Therapeutics, Inc. 8-K

What Happened

• Larimar Therapeutics, Inc. announced an underwritten public offering of common stock. Under an underwriting agreement dated February 25, 2026, the company offered 20,000,000 firm shares at $5.00 per share and granted the underwriters a 30‑day option for an additional 3,000,000 shares, which was fully exercised on February 26, 2026. The total of 23,000,000 shares at $5.00 equals $115.0 million in gross proceeds; net proceeds after underwriting discounts, commissions and estimated expenses are expected to be approximately $107.6 million. The offering was arranged by J.P. Morgan Securities LLC and Guggenheim Securities, LLC as joint bookrunning managers and was expected to close on February 27, 2026.

Key Details

• Offering size: 20,000,000 firm shares + 3,000,000 option shares (option exercised in full).
• Price per share: $5.00.
• Gross proceeds: $115.0 million; expected net proceeds: ~ $107.6 million.
• Underwriters: J.P. Morgan Securities LLC and Guggenheim Securities, LLC (joint bookrunners); offering expected to close Feb 27, 2026.

Why It Matters

• The offering injects fresh capital—about $107.6M net—into Larimar, which the company can use to fund operations, clinical programs or other corporate needs. Because all shares are newly issued by the company (a primary offering), existing shareholders will experience dilution as the total share count increases. The filing also discloses the standard underwriting terms and legal opinion supporting the issuance, which are routine for a transaction of this type.